SCHEMBL7704910

SCHEMBL7704910

CC1=C(N)Nc2cc(CN(Cc3ccccc3)C(=O)OC(C)(C)C)ccc2O1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.45
HDAC3 O15379 2/20 0.45
HDAC2 Q92769 2/20 0.45
NCOR2 Q9Y618 2/20 0.45
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
CTSS P25774 1/20 0.36
BACE1 P56817 3/20 0.35
PTGES O14684 1/20 0.35
AKT1 P31749 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
ABCB1 P08183 1/20 0.34
AGTR1 P30556 1/20 0.34
AGTR2 P50052 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7708189 0.93 HDAC3 (0.37) HDAC1HDAC3HDAC2NCOR2ALDH1A1
SCHEMBL7711366 0.93 HDAC1 (0.37) HDAC1HDAC3HDAC2NCOR2ALDH1A1
SCHEMBL7708353 0.91 GRM2 (0.37) HDAC1HDAC3HDAC2NCOR2ALDH1A1
SCHEMBL7704965 0.91 HDAC3 (0.36) HDAC1HDAC3HDAC2NCOR2ALDH1A1
SCHEMBL7704902 0.91 RIPK1 (0.37) HDAC1HDAC3HDAC2NCOR2SMN1; SMN2
SCHEMBL7711248 0.91 RIPK1 (0.37) HDAC1HDAC3HDAC2NCOR2ALDH1A1
SCHEMBL7704946 0.90 ALDH1A1 (0.38) HDAC1HDAC3HDAC2NCOR2ALDH1A1
SCHEMBL7711328 0.90 HDAC3 (0.35) HDAC1HDAC3HDAC2NCOR2MEN1
SCHEMBL7704988 0.90 HDAC3 (0.36) HDAC1HDAC3HDAC2NCOR2ALDH1A1
SCHEMBL7710867 0.90 ALDH1A1 (0.38) HDAC1HDAC3HDAC2NCOR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed